TY - JOUR
T1 - Cellular and Humoral Responses Follow-up for 8 Months after Vaccination with mRNA-Based Anti-SARS-CoV-2 Vaccines
AU - Gil-Manso, Sergio
AU - Carbonell, Diego
AU - Pérez-Fernández, Verónica Astrid
AU - López-Esteban, Rocío
AU - Alonso, Roberto
AU - Muñoz, Patricia
AU - Ochando, Jordi
AU - Sánchez-Arcilla, Ignacio
AU - Bellón, Jose M.
AU - Correa-Rocha, Rafael
AU - Pion, Marjorie
N1 - Funding Information:
This work was partially supported by grants from the Instituto de Salud Carlos III (ISCIII) (PI18/00506; COV20/00063), co-funded by ERDF (FEDER) Funds from the European Commission, “A way of making Europe”. This work was partially financed by the Madrid Community grant B2017/BMD3727 and the IiSGM Intramural grant PI-MP-2018. This work was partially funded by a grant from “Fundación Familia Alonso” (FFA-FIBHGM-2019). S.G-M. was supported by the Youth Employment Program, co-financed by the Madrid community and FEDER Founds (PEJ-2020-AI/BMD-17954), and by the ACT4COVID consortium (CellNex funding). The funders had no role in study design, data collection and analysis, decision to publish, or manuscript preparation.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/7
Y1 - 2022/7
N2 - Vaccination against SARS-CoV-2 has become the main method of reducing mortality and severity of COVID-19. This work aims to study the evolution of the cellular and humoral responses conferred by two mRNA vaccines after two doses against SARS-CoV-2. On days 30 and 240 after the second dose of both vaccines, the anti-S antibodies in plasma were evaluated from 82 volunteers vaccinated with BNT162b2 and 68 vaccinated with mRNA-1273. Peripheral blood was stimulated with peptides encompassing the entire SARS-CoV-2 Spike sequence. IgG Anti-S antibodies (humoral) were quantified on plasma, and inflammatory cytokines (cellular) were measured after stimulation. We observed a higher response (both humoral and cellular) with the mRNA-1273 vaccine. Stratifying by age and gender, differences between vaccines were observed, especially in women under 48 and men over 48 years old. Therefore, this work could help to set up a vaccination strategy that could be applied to confer maximum immunity.
AB - Vaccination against SARS-CoV-2 has become the main method of reducing mortality and severity of COVID-19. This work aims to study the evolution of the cellular and humoral responses conferred by two mRNA vaccines after two doses against SARS-CoV-2. On days 30 and 240 after the second dose of both vaccines, the anti-S antibodies in plasma were evaluated from 82 volunteers vaccinated with BNT162b2 and 68 vaccinated with mRNA-1273. Peripheral blood was stimulated with peptides encompassing the entire SARS-CoV-2 Spike sequence. IgG Anti-S antibodies (humoral) were quantified on plasma, and inflammatory cytokines (cellular) were measured after stimulation. We observed a higher response (both humoral and cellular) with the mRNA-1273 vaccine. Stratifying by age and gender, differences between vaccines were observed, especially in women under 48 and men over 48 years old. Therefore, this work could help to set up a vaccination strategy that could be applied to confer maximum immunity.
KW - COVID-19
KW - SARS-CoV-2
KW - cellular responses
KW - humoral responses
KW - mRNA-vaccines
UR - http://www.scopus.com/inward/record.url?scp=85137288496&partnerID=8YFLogxK
U2 - 10.3390/biomedicines10071676
DO - 10.3390/biomedicines10071676
M3 - Article
AN - SCOPUS:85137288496
VL - 10
JO - Biomedicines
JF - Biomedicines
SN - 2227-9059
IS - 7
M1 - 1676
ER -